|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Veterinary medicine
|
|
Name of medicinal product:
|
Advantix
|
|
Active substances:
|
|
|
ATC code:
|
QP53AC88
|
|
Dosage form:
|
spot-on solution
|
|
Strength:
|
1250mg+250mg 2.5ml
|
|
Legal status for supply*:
|
Not subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
 (last updated January 28, 2022)
|
|
Package information leaflet (PIL):
|
EST (last updated April 4, 2023)
|
|
Labelling:
|
(last updated January 28, 2022)
|
|
Indication:
|
For the treatment and prevention of flea (Ctenocephalides canis, Ctenocephalides felis) infestation.
Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks. The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
For the treatment of biting lice (Trichodectes canis).
The product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for four weeks, and Dermacentor reticulatus for three weeks).
By repelling and killing the tick vector Rhipicephalus sanguineus, the product reduces the likelihood of transmission of the pathogen Ehrlichia canis, thereby reducing the risk of canine ehrlichiosis. The reduction in risk has been shown in studies to commence from 3 days following application of the product and to persist for 4 weeks.
Ticks already on the dog may not be killed within two days after treatment and may remain attached and visible. Therefore the removal of ticks already on the dog at the time of treatment is recommended, in order to prevent them from attaching and having a blood meal.
One treatment provides repellent (anti-feeding) activity against sand flies (Phlebotomus papatasi for two weeks and Phlebotomus perniciosus for three weeks), against mosquitoes (Aedes aegypti for two weeks and Culex pipiens for four weeks) and against stable flies (Stomoxys calcitrans) for four weeks.
Reduction of the risk of infection with Leishmania infantum via transmission by sandflies (Phlebotomus perniciosus) for up to 3 weeks. The effect is indirect due to product’s activity against the vector.
|
|
Safety features:
|
No
|
|
Marketing authorization holder:
|
Bayer Animal Health GmbH
|
|
Marketing authorization number:
|
2332
|
|
Marketing authorization issued on:
|
January 27, 2022
|
|
Marketing authorization expires on:
|
Unlimited
|
|
Marketing authorization procedure type:
|
National
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1136821
|
Advantix
|
spot-on solution
|
1250mg +250mg 2.5ml 2.5ml 1TK
|
OTC
|
|
|
25.08.2023
|
|
|
|
1136832
|
Advantix
|
spot-on solution
|
1250mg +250mg 2.5ml 2.5ml 2TK
|
OTC
|
|
|
|
|
|
|
1136843
|
Advantix
|
spot-on solution
|
1250mg +250mg 2.5ml 2.5ml 3TK
|
OTC
|
|
|
|
|
|
|
1136854
|
Advantix
|
spot-on solution
|
1250mg +250mg 2.5ml 2.5ml 4TK
|
OTC
|
|
|
15.03.2023
|
|
|
|
1136865
|
Advantix
|
spot-on solution
|
1250mg +250mg 2.5ml 2.5ml 6TK
|
OTC
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere